Description: Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Home Page: www.avalon-globocare.com
ALBT Technical Analysis
4400 Route 9 South
Freehold,
NJ
07728
United States
Phone:
732 780 4400
Officers
| Name | Title |
|---|---|
| Dr. David K. Jin M.D., Ph.D. | CEO, Pres & Director |
| Ms. Luisa Ingargiola | Chief Financial Officer |
| Ms. Meng Li | COO, Sec. & Director |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.4262 |
| Price-to-Sales TTM: | 35.6002 |
| IPO Date: | 2016-12-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |